Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

This study is testing a combination of two cancer drugs — olaparib (a PARP inhibitor) and pembrolizumab (an immunotherapy) — in people with advanced uveal melanoma, a rare form of eye cancer that has spread to other parts of the body. **You may be eligible if...** - You are 18 or older with metastatic uveal melanoma confirmed by biopsy - Your cancer can be measured on imaging scans - You are in generally good health (able to carry out normal activity with minor restrictions) - You can swallow pills - You agree to use contraception during and after treatment **You may NOT be eligible if...** - You have previously been treated with immunotherapy drugs (anti-PD-1/PD-L1) specifically for uveal melanoma - You have previously received a PARP inhibitor - You have active, uncontrolled brain metastases - You have an active autoimmune disease requiring systemic treatment - You are pregnant, breastfeeding, or have HIV, active Hepatitis B or C, or active tuberculosis - You have had an organ transplant Talk to your doctor to see if this trial is right for you.